DHT Holdings, Inc. (DHT) Forms $3.74 Double Bottom; Palo Alto Investors Trimmed By $19.80 Million Its Amicus Therapeutics (FOLD) Position

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Logo

DHT Holdings, Inc. (DHT) formed double bottom with $3.44 target or 8.00% below today’s $3.74 share price. DHT Holdings, Inc. (DHT) has $536.96 million valuation. The stock decreased 0.80% or $0.03 during the last trading session, reaching $3.74. About 328,999 shares traded. DHT Holdings, Inc. (NYSE:DHT) has declined 16.89% since May 18, 2017 and is downtrending. It has underperformed by 28.44% the S&P500.

Palo Alto Investors Llc decreased Amicus Therapeutics Inc (FOLD) stake by 19.06% reported in 2017Q4 SEC filing. Palo Alto Investors Llc sold 1.41 million shares as Amicus Therapeutics Inc (FOLD)’s stock rose 0.85%. The Palo Alto Investors Llc holds 6.01M shares with $86.43M value, down from 7.42M last quarter. Amicus Therapeutics Inc now has $3.12 billion valuation. The stock increased 3.11% or $0.5 during the last trading session, reaching $16.56. About 3.94 million shares traded or 45.65% up from the average. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 90.40% since May 18, 2017 and is uptrending. It has outperformed by 78.85% the S&P500.

Analysts await DHT Holdings, Inc. (NYSE:DHT) to report earnings on August, 14. They expect $-0.16 EPS, down 500.00% or $0.20 from last year’s $0.04 per share. After $-0.06 actual EPS reported by DHT Holdings, Inc. for the previous quarter, Wall Street now forecasts 166.67% negative EPS growth.

Among 11 analysts covering DHT Holdings (NYSE:DHT), 5 have Buy rating, 1 Sell and 5 Hold. Therefore 45% are positive. DHT Holdings has $11 highest and $3.2000 lowest target. $6.49’s average target is 73.53% above currents $3.74 stock price. DHT Holdings had 33 analyst reports since September 1, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, July 27 by Jefferies. The company was maintained on Friday, April 21 by Maxim Group. Seaport Global maintained DHT Holdings, Inc. (NYSE:DHT) on Wednesday, February 7 with “Buy” rating. The stock has “Neutral” rating by JP Morgan on Friday, April 20. Stifel Nicolaus maintained DHT Holdings, Inc. (NYSE:DHT) rating on Wednesday, August 9. Stifel Nicolaus has “Hold” rating and $5.2500 target. The rating was maintained by Stifel Nicolaus with “Hold” on Friday, July 7. The stock of DHT Holdings, Inc. (NYSE:DHT) has “Hold” rating given on Monday, January 30 by Stifel Nicolaus. J.P. Morgan downgraded the stock to “Hold” rating in Friday, April 20 report. Jefferies maintained DHT Holdings, Inc. (NYSE:DHT) on Friday, April 20 with “Buy” rating. The rating was initiated by Jefferies on Monday, December 18 with “Buy”.

Among 9 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Amicus Therapeutics had 22 analyst reports since August 18, 2015 according to SRatingsIntel. The firm has “Buy” rating by Cowen & Co given on Tuesday, July 11. As per Monday, August 31, the company rating was maintained by Leerink Swann. Chardan Capital Markets downgraded it to “Neutral” rating and $17 target in Wednesday, September 16 report. Chardan Capital Markets upgraded Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Monday, October 5 to “Buy” rating. Leerink Swann maintained the shares of FOLD in report on Monday, October 5 with “Outperform” rating. The firm earned “Buy” rating on Tuesday, September 1 by Cowen & Co. Robert W. Baird maintained the shares of FOLD in report on Wednesday, February 7 with “Buy” rating. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) has “Buy” rating given on Tuesday, August 18 by Zacks. The firm earned “Buy” rating on Wednesday, May 18 by Bank of America. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Overweight” rating by JP Morgan on Tuesday, September 8.

Palo Alto Investors Llc increased Shire Plc (NASDAQ:SHPG) stake by 5,600 shares to 135,800 valued at $21.07M in 2017Q4. It also upped Bioverativ Inc stake by 53,100 shares and now owns 264,400 shares. Alexion Pharmaceuticals Inc (NASDAQ:ALXN) was raised too.

Investors sentiment decreased to 1.21 in 2017 Q4. Its down 1.12, from 2.33 in 2017Q3. It fall, as 25 investors sold FOLD shares while 48 reduced holdings. 25 funds opened positions while 63 raised stakes. 197.59 million shares or 2.54% more from 192.70 million shares in 2017Q3 were reported. Goldman Sachs, New York-based fund reported 1.56M shares. Dimensional Fund LP holds 0% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 347,563 shares. Citigroup, a New York-based fund reported 12,518 shares. Legal General Group Public Ltd has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). J Goldman Company Limited Partnership holds 0.17% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 224,122 shares. Price T Rowe Associate Md holds 9.06M shares or 0.02% of its portfolio. Highland Cap Mgmt LP reported 292,000 shares stake. 192,978 were accumulated by Raymond James And Assocs. New York-based Orbimed Advsr Ltd Llc has invested 1.01% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Moreover, Northern Tru Corporation has 0.01% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 1.97 million shares. Vanguard Group holds 13.63 million shares. Qs Invsts Limited, New York-based fund reported 159,008 shares. 127,025 were accumulated by Manufacturers Life Ins Communications The. Trexquant Limited Partnership has 0.04% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 25,261 shares. Axa has 0.03% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 517,990 shares.

Since December 11, 2017, it had 3 insider buys, and 19 insider sales for $3.49 million activity. On Thursday, April 12 Barth Jay sold $73,602 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 5,000 shares. Another trade for 32,500 shares valued at $517,371 was sold by Campbell Bradley L. Crowley John F also sold $164,973 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares. Baird William D III also sold $142,648 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Monday, April 2. RAAB MICHAEL sold $72,058 worth of stock or 5,000 shares. 8,750 Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares with value of $131,250 were sold by Quimi Daphne. $750,000 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) was sold by Do Hung on Tuesday, April 17.

Analysts await Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report earnings on August, 6. They expect $-0.33 EPS, up 2.94% or $0.01 from last year’s $-0.34 per share. After $-0.28 actual EPS reported by Amicus Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 17.86% negative EPS growth.

DHT Holdings, Inc. (NYSE:DHT) Ratings Chart